{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:46:38Z","timestamp":1787237198482,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["smedj"],"published-print":{"date-parts":[[2020,12,28]]},"DOI":"10.11622\/smedj.2019143","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T01:58:28Z","timestamp":1572832708000},"page":"641-646","source":"Crossref","is-referenced-by-count":14,"title":["SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation"],"prefix":"10.4103","volume":"61","author":[{"name":"COOL-AF Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Krittayaphong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Winijkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pirapatdit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Chiewvit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Komoltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Boonyapisit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Arunsiriwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Bunyapipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Apiyasawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Rattanasumawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Yindeengam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1378\/chest.11-2888","article-title":"The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe","volume":"142","author":"Lip","year":"2012","unstructured":"1. Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012; 142:1489-98.","journal-title":"Chest"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.rec.2016.11.033","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"70","author":"Kirchhof","year":"2017","unstructured":"2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed) 2017; 70:50.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref2","unstructured":"3. January CT, Wann LS, Alpert JS, et al; American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1-76."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.hrthm.2013.03.017","article-title":"Stroke prevention in atrial fibrillation--an Asian stroke perspective","volume":"10","author":"Tse","year":"2013","unstructured":"4. Tse HF, Wang YJ, Ahmed Ai-Abdullah M, et al. Stroke prevention in atrial fibrillation--an Asian stroke perspective. Heart Rhythm 2013; 10:1082-8.","journal-title":"Heart Rhythm"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","unstructured":"5. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50:309-15.","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ijcard.2016.08.236","article-title":"Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry","volume":"223","author":"Oh","year":"2016","unstructured":"6. Oh S, Goto S, Accetta G, et al; GARFIELD-AF Investigators. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry. Int J Cardiol 2016; 223:543-7.","journal-title":"Int J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","article-title":"2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"Chiang","year":"2017","unstructured":"7. Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm 2017; 33:345-67.","journal-title":"J Arrhythm"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Haas S, Ten Cate H, Accetta G, et al; GARFIELD-AF Investigators. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One 2016; 11:e0164076.","DOI":"10.1371\/journal.pone.0164076"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score","volume":"144","author":"Apostolakis","year":"2013","unstructured":"9. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144:1555-63.","journal-title":"Chest"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.hrthm.2017.11.026","article-title":"Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: a review","volume":"15","author":"Zulkifly","year":"2018","unstructured":"10. Zulkifly H, Lip GYH, Lane DA. Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: a review. Heart Rhythm 2018; 15: 615-23.","journal-title":"Heart Rhythm"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","unstructured":"11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri\u00ebt E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69:236-9.","journal-title":"Thromb Haemost"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"SJ","year":"2008","unstructured":"12. Connolly SJ, Pogue J, Eikelboom J, et al; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029-37.","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1160\/TH13-11-0948","article-title":"Stroke prevention in atrial fibrillation: an Asian perspective","volume":"111","author":"Chiang","year":"2014","unstructured":"13. Chiang CE, Wang KL, Lip GYH. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111:789-97.","journal-title":"Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1212\/WNL.0000000000000245","article-title":"Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study","volume":"82","author":"Poli","year":"2014","unstructured":"14. Poli D, Antonucci E, Dentali F, et al; Italian Federation of Anticoagulation Clinics (FCSA). Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. Neurology 2014; 82:1020-6.","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jfma.2016.10.005","article-title":"2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation","volume":"115","author":"Chiang","year":"2016","unstructured":"15. Chiang CE, Wu TJ, Ueng KC, et al. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc 2016; 115:893-952.","journal-title":"J Formos Med Assoc"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4070\/kcj.2015.45.1.9","article-title":"The Korean Heart Rhythm Society's 2014 statement on antithrombotic therapy for patients with nonvalvular atrial fibrillation: Korean Heart Rhythm Society","volume":"45","author":"Jung","year":"2015","unstructured":"16. Jung BC, Kim NH, Nam GB, et al. The Korean Heart Rhythm Society's 2014 statement on antithrombotic therapy for patients with nonvalvular atrial fibrillation: Korean Heart Rhythm Society. Korean Circ J 2015; 45:9-19.","journal-title":"Korean Circ J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","article-title":"Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013)","volume":"78","author":"Joint Working Group","year":"2014","unstructured":"17. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 2014; 78:1997-2021.","journal-title":"Circ J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jfma.2016.05.007","article-title":"Factors driving the use of warfarin and non- vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"116","author":"MM","year":"2017","unstructured":"18. Hu MM, Wang J, Chien KL, et al. Factors driving the use of warfarin and non- vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. J Formos Med Assoc 2017; 116:276-86.","journal-title":"J Formos Med Assoc"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Aribou ZM, Mondry A. Anticoagulation needs in Asians with atrial fibrillation: a mythbuster. Ann Acad Med Singapore 2014; 43:275-8.","DOI":"10.47102\/annals-acadmedsg.V43N5p275"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1067\/mcp.2003.26a","article-title":"Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients","volume":"73","author":"Takahashi","year":"2003","unstructured":"20. Takahashi H, Wilkinson GR, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73:253-63.","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10928-009-9138-4","article-title":"Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin","volume":"37","author":"Yuen","year":"2010","unstructured":"21. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn 2010; 37:3-24.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref21","unstructured":"22. Chen KP, Huang CX, Huang DJ, et al. Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: a prospective, multi-center, randomized, controlled study. Chin Med J (Engl) 2012; 125:4355-60."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Chan PH, Hai JJ, Chan EW, et al. Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence. PLoS One 2016; 11:e0150674.","DOI":"10.1371\/journal.pone.0150674"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.08.030","article-title":"The sex, age, medical history, treatment, tobacco use, race risk (SAMe TT2R2) score predicts warfarin control in a Singaporean population","volume":"26","author":"Bernaitis","year":"2017","unstructured":"24. Bernaitis N, Ching CK, Chen L, et al. The sex, age, medical history, treatment, tobacco use, race risk (SAMe TT2R2) score predicts warfarin control in a Singaporean population. J Stroke Cerebrovasc Dis 2017; 26:64-9.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1378\/chest.13-2109","article-title":"The SAMe-TT2R2 score: far from clinical application","volume":"145","author":"Zhang","year":"2014","unstructured":"25. Zhang H, Yang Y, Zhu J. The SAMe-TT2R2 score: far from clinical application. Chest 2014; 145:418-9.","journal-title":"Chest"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. van Miert JHA, Bos S, Veeger NJGM, Meijer K. Clinical usefulness of the SAMe- TT2R2 score: a systematic review and simulation meta-analysis. PLoS One 2018; 13:e0194208.","DOI":"10.1371\/journal.pone.0194208"}],"container-title":["Singapore Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.smj.org.sg\/article\/same-tt2r2-score-prediction-suboptimal-time-therapeutic-range-thai-population-atrial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T08:33:13Z","timestamp":1664785993000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.smj.org.sg\/article\/same-tt2r2-score-prediction-suboptimal-time-therapeutic-range-thai-population-atrial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,28]]}},"URL":"https:\/\/doi.org\/10.11622\/smedj.2019143","relation":{},"ISSN":["0037-5675"],"issn-type":[{"value":"0037-5675","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,28]]}}}